Review



mgmt promoter methylation test  (Kiyatec Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Kiyatec Inc mgmt promoter methylation test
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Test, supplied by Kiyatec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+test/mgmt+methylation+test/pmc11358395-240-14-11
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation test - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma"

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    Journal: Scientific Reports

    doi: 10.1038/s41598-024-68801-0

    3D Predict Glioma identified those patients with an unmethylated MGMT promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Figure Legend Snippet: 3D Predict Glioma identified those patients with an unmethylated MGMT promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.

    Techniques Used: Methylation

    3D Predict Glioma stratified patient response regardless of the MGMT promoter methylation test used. ( a ) bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( b ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( c,e ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( c ) and pyrosequencing ( e ) tested populations. ( d,f ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( d ) and pyrosequencing ( f ) tested populations.
    Figure Legend Snippet: 3D Predict Glioma stratified patient response regardless of the MGMT promoter methylation test used. ( a ) bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( b ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( c,e ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( c ) and pyrosequencing ( e ) tested populations. ( d,f ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( d ) and pyrosequencing ( f ) tested populations.

    Techniques Used: Methylation

    Standardization of MGMT promoter methylation testing affects MGMT promoter methylation categorization. ( a,b ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the GBM population as a conglomerate of multiple test types ( a ) and tested with Kiyatec’s MGMT methylation test ( b ). ( c ) Bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( d ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( e,g ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( e ) and pyrosequencing ( g ) tested populations. ( f,h ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( f ) and pyrosequencing ( h ) tested populations.
    Figure Legend Snippet: Standardization of MGMT promoter methylation testing affects MGMT promoter methylation categorization. ( a,b ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the GBM population as a conglomerate of multiple test types ( a ) and tested with Kiyatec’s MGMT methylation test ( b ). ( c ) Bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( d ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( e,g ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( e ) and pyrosequencing ( g ) tested populations. ( f,h ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( f ) and pyrosequencing ( h ) tested populations.

    Techniques Used: Methylation

    Demographics of patients at clinical correlation, Irrespective of study predicted treatment response.
    Figure Legend Snippet: Demographics of patients at clinical correlation, Irrespective of study predicted treatment response.

    Techniques Used: Histopathology, Mutagenesis, Methylation

    Related Articles

    Methylation:

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma
    Article Snippet: .. When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites. .. Briefly, DNA was isolated using the QIAamp DNA isolation kit (Qiagen) from either frozen cell pellets or cryopreserved cells previously isolated from the same patient samples as used for 3D Predict Glioma testing.

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma.
    Article Snippet: .. MGMT promoter methylation testing When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites. .. Briefly, DNA was isolated using the QIAamp DNA isolation kit (Qiagen) from either frozen cell pellets or cryopreserved cells previously isolated from the same patient samples as used for 3D Predict Glioma testing.



    Similar Products

    mgmt promoter methylation test  (Kiyatec Inc)
    90
    Kiyatec Inc mgmt promoter methylation test
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Test, supplied by Kiyatec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+test/mgmt+methylation+test/pmc11358395-240-14-11
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mgmt promoter methylation status testing  (Covance)
    90
    Covance mgmt promoter methylation status testing
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Status Testing, supplied by Covance, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+test/mgmt+promoter+methylation+status+testing/pm35419607-51-6-14
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation status testing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    qmsp-based mgmt promoter methylation testing  (MDxHealth)
    90
    MDxHealth qmsp-based mgmt promoter methylation testing
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Qmsp Based Mgmt Promoter Methylation Testing, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+test/mgmt+promoter+methylation+testing/pm33113214-56-1-16
    Average 90 stars, based on 1 article reviews
    qmsp-based mgmt promoter methylation testing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mgmt promoter methylation testing free of charge  (MDxHealth)
    90
    MDxHealth mgmt promoter methylation testing free of charge
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Testing Free Of Charge, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+test/mgmt+promoter+methylation+testing/pmc07086476-420-51-48
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation testing free of charge - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mgmt promoter methylation testing  (MDxHealth)
    90
    MDxHealth mgmt promoter methylation testing
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Testing, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+test/mgmt+promoter+methylation+testing/pmc07086476-4830-3-0
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation testing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    3D Predict Glioma identified those patients with an unmethylated MGMT promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: 3D Predict Glioma identified those patients with an unmethylated MGMT promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Methylation

    3D Predict Glioma stratified patient response regardless of the MGMT promoter methylation test used. ( a ) bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( b ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( c,e ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( c ) and pyrosequencing ( e ) tested populations. ( d,f ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( d ) and pyrosequencing ( f ) tested populations.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: 3D Predict Glioma stratified patient response regardless of the MGMT promoter methylation test used. ( a ) bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( b ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( c,e ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( c ) and pyrosequencing ( e ) tested populations. ( d,f ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( d ) and pyrosequencing ( f ) tested populations.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Methylation

    Standardization of MGMT promoter methylation testing affects MGMT promoter methylation categorization. ( a,b ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the GBM population as a conglomerate of multiple test types ( a ) and tested with Kiyatec’s MGMT methylation test ( b ). ( c ) Bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( d ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( e,g ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( e ) and pyrosequencing ( g ) tested populations. ( f,h ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( f ) and pyrosequencing ( h ) tested populations.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: Standardization of MGMT promoter methylation testing affects MGMT promoter methylation categorization. ( a,b ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the GBM population as a conglomerate of multiple test types ( a ) and tested with Kiyatec’s MGMT methylation test ( b ). ( c ) Bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( d ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( e,g ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( e ) and pyrosequencing ( g ) tested populations. ( f,h ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( f ) and pyrosequencing ( h ) tested populations.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Methylation

    Demographics of patients at clinical correlation, Irrespective of study predicted treatment response.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: Demographics of patients at clinical correlation, Irrespective of study predicted treatment response.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Histopathology, Mutagenesis, Methylation